ADHD Medications Linked to Reduction in Psychiatric Hospitalizations
By Elana Gotkine HealthDay Reporter
FRIDAY, March 22, 2024 -- For adolescents and adults with attention-deficit/hyperactivity disorder (ADHD), the use of ADHD medications is associated with fewer psychiatric and nonpsychiatric hospitalizations, according to a study published online March 20 in JAMA Network Open.
Heidi Taipale, Ph.D., from the Karolinska Institutet in Stockholm, and colleagues examined the association between use of specific ADHD medications and hospitalization outcomes and work disability in a nationwide register-based cohort study involving adolescents and adults with ADHD during 2006 to 2021. The study cohort included 221,714 persons with ADHD.
The most commonly used ADHD medication was methylphenidate, followed by lisdexamphetamine (68.5 and 35.2 percent). The researchers found that amphetamine, lisdexamphetamine, ADHD drug polytherapy, dexamphetamine, and methylphenidate were associated with a reduced risk for psychiatric hospitalizations (adjusted hazard ratios, 0.74, 0.80, 0.85, 0.88, and 0.93, respectively). There were no associations seen for modafinil, atomoxetine, clonidine, or guanfacine. Use of dexamphetamine, lisdexamphetamine, and methylphenidate was associated with a reduced risk for suicidal behavior (adjusted hazard ratios, 0.69, 0.76, and 0.92, respectively). Amphetamine, lisdexamphetamine, polytherapy, dexamphetamine, methylphenidate, and atomoxetine were associated with a reduced risk for nonpsychiatric hospitalization. Regarding work disability, the results were only significant for use of atomoxetine (adjusted hazard ratio, 0.89), especially for those aged 16 to 29 years (adjusted hazard ratio, 0.82).
"Considering the high prevalence of psychiatric comorbidity in persons with ADHD, these results suggest that ADHD medication use can reduce morbidity in adolescents and adults with ADHD," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Allergy-Related Psychological Distress Common
TUESDAY, July 2, 2024 -- Psychological distress related to food allergies (FA) is common globally, according to a study published online June 21 in Allergy. Rebecca C...
Health Status, Mental Health Worsened in U.S. Transgender Adults From 2014 to 2022
TUESDAY, June 25, 2024 -- Health status, mental health, and health inequities worsened in the United States from 2014 to 2022 among transgender (TGD) adults, according to a...
ADHD Meds May Help Control Opioid Use Disorder in Pregnancy
TUESDAY, June 25, 2024 -- Psychostimulants may help opioid use disorder (OUD) outcomes in pregnant women, according to a study published online June 11 in Nature Mental...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.